Make your money go further for just 25p per day

PREMIUM
AIM IHT

Fevertree Drinks: is the valuation justified?

Fever-Tree Blood orange

Shares in the premium mixer group rose strongly as it reported in-line results and, more significantly, reiterated guidance for the current year. With new product launches coming thick and fast and a greatly expanded distribution in the key US market, the future looks promising, but does all this justify the rich valuation?


To the great joy (and relief) of the stock market, Fevertree Drinks (AIM:FEVR), creator of superlative premium mixers, reported in-line results and re-iterated its full year guidance, sending its shares sharply higher.

As well as extending its position as the number one premium mixer brand globally, Fevertree has also started to develop several key adjacent opportunities for the brand, an important aspect to help justify its sky-high valuation.

Group revenue for the…

Continue reading our content…

Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
  • Unlimited access to our market-beating portfolios
  • In-depth coverage of many of the world’s great companies
  • Unique insights from our top research team
Register FREE for access to limited content.
  • Company and markets insights
  • Sponsored content
  • Podcasts

Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Fevertree Drinks

Episode 33 of the Investor’s Champion Podcast

15/09/2024 · Podcasts

In this episode of the Investors Champion Podcast, hosts Lee and Chris focus on news from…


US growth | Legal winner | Dividend delights

13/09/2024 · Company Insights

News covered here includes our assessment of interim results from Fevertree, which disappointed the market, despite…


More Company Insights

Elderly challenges | Demotion | Australian boost

21/11/2024 · Churchill China · CVS Group · Renold · Tracsis

Bonkers Bargains: poised to recover with a new CEO

20/11/2024 · James Cropper

Improving returns | Questionable business models

Sign-up to our free email updates

SIGN UP